| EQUITY
|
|
|
|
|
|
|
|
(1) ORGANIZATION AND BASIS OF PRESENTATION
Organization
Exact Sciences Corporation (“Exact,” “we,” “us” or the “Company”) was incorporated in February 1995. Exact is a molecular diagnostics company currently focused on the early detection and prevention of colorectal cancer. The Company’s non-invasive stool-based DNA (sDNA) screening technology includes proprietary and patented methods that isolate and analyze human DNA present in stool to screen for the presence of colorectal pre-cancer and cancer.
Basis of Presentation
The accompanying condensed financial statements of the Company are unaudited and have been prepared on a basis substantially consistent with the Company’s audited financial statements and notes as of and for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K (the “2012 Form 10-K”). These condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and follow the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. In the opinion of management, all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair presentation of the results of operations have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results of the Company’s operations for any other interim period or for a full fiscal year. The statements should be read in conjunction with the audited financial statements and related notes included in the 2012 Form 10-K. Management has evaluated subsequent events for disclosure or recognition in the accompanying financial statements up to the filing of this report.
|
(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers cash on hand, demand deposits in bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. The Company had no restricted cash at June 30, 2013 and December 31, 2012.
Marketable Securities
Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Marketable equity securities and debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the straight-line method, which approximates the effective interest method. Such amortization is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in investment income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.
At June 30, 2013 and December 31, 2012, the Company’s investments were comprised of fixed income investments and all were deemed available-for-sale. The objectives of the Company’s investment strategy are to provide liquidity and safety of principal while striving to achieve the highest rate of return consistent with these two objectives. The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. All of the Company’s investments are considered current. There were no realized losses for the six months ended June 30, 2013 and June 30, 2012. Realized gains were $2,760 and $2,528 for the six months ended June 30, 2013 and 2012, respectively. Unrealized gains or losses on investments are recorded in other comprehensive loss.
Available-for-sale securities at June 30, 2013 consist of the following:
|
|
June 30, 2013 |
| ||||||||||
(In thousands) |
|
Amortized |
|
Gains in |
|
Losses in |
|
Estimated |
| ||||
U.S. government agency securities |
|
$ |
49,156 |
|
$ |
40 |
|
$ |
— |
|
$ |
49,196 |
|
Corporate bonds |
|
73,771 |
|
— |
|
(35 |
) |
73,736 |
| ||||
Certificates of deposit |
|
8,272 |
|
12 |
|
— |
|
8,284 |
| ||||
Commercial paper |
|
4,995 |
|
— |
|
— |
|
4,995 |
| ||||
Total available-for-sale securities |
|
$ |
136,194 |
|
$ |
52 |
|
$ |
(35 |
) |
$ |
136,211 |
|
Available-for-sale securities at December 31, 2012 consist of the following:
|
|
December 31, 2012 |
| ||||||||||
(In thousands) |
|
Amortized |
|
Gains in |
|
Losses in |
|
Estimated |
| ||||
U.S. government agency securities |
|
$ |
44,270 |
|
$ |
38 |
|
$ |
— |
|
$ |
44,308 |
|
Corporate bonds |
|
43,303 |
|
27 |
|
— |
|
43,330 |
| ||||
Certificates of deposit |
|
5,926 |
|
13 |
|
— |
|
5,939 |
| ||||
Commercial paper |
|
1,199 |
|
— |
|
— |
|
1,199 |
| ||||
Total available-for-sale securities |
|
$ |
94,698 |
|
$ |
78 |
|
$ |
— |
|
$ |
94,776 |
|
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
|
|
June 30, |
| ||
(In thousands) |
|
2013 |
|
2012 |
|
Shares issuable upon exercise of stock options |
|
6,249 |
|
6,320 |
|
Shares issuable upon exercise of outstanding warrants (1) |
|
155 |
|
325 |
|
Shares issuable upon the release of restricted stock awards |
|
875 |
|
884 |
|
Shares issuable upon the vesting of restricted stock awards related to a licensing agreement |
|
49 |
|
73 |
|
|
|
7,328 |
|
7,602 |
|
(1) At June 30, 2013, represents warrants to purchase 80,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement. At June 30, 2012, represents warrants to purchase 250,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.
Revenue Recognition
License fees. License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period. As more fully described in the 2012 Form 10-K, in connection with our January 2009 strategic transaction with Genzyme Corporation, Genzyme agreed to pay us a total of $18.5 million, of which $16.65 million was paid on January 27, 2009 and $1.85 million was subject to a holdback by Genzyme to satisfy certain potential indemnification obligations in exchange for the assignment and licensing of certain intellectual property to Genzyme. The Company’s on-going performance obligations to Genzyme under the Collaboration, License and Purchase Agreement (the “CLP Agreement”), as described below, including its obligation to deliver through licenses certain intellectual property improvements to Genzyme, if improvements are made during the initial five-year collaboration period, were deemed to be undelivered elements of the CLP Agreement on the date of closing. Accordingly, the Company deferred the initial $16.65 million in cash received at closing and is amortizing that up-front payment on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014. The Company received the first holdback amount of $962,000, which included accrued interest due, from Genzyme during the first quarter of 2010. The Company received the second holdback amount of $934,250, which included accrued interest due, from Genzyme during the third quarter of 2010. The amounts were deferred and are being amortized on a straight-line basis into revenue over the remaining term of the collaboration at the time of receipt.
In addition, Genzyme purchased 3,000,000 shares of common stock on January 27, 2009 for $2.00 per share, representing a premium of $0.51 per share above the closing price of the Company’s common stock on that date of $1.49 per share. The aggregate premium paid by Genzyme over the closing price of the Company’s common stock on the date of the transaction of $1.53 million is deemed to be a part of the total consideration for the CLP Agreement. Accordingly, the Company deferred the aggregate $1.53 million premium and is amortizing that amount on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014.
The Company recognized approximately $1.0 million in license fee revenue in connection with the amortization of the up-front payments from Genzyme, during each of the three months ended June 30, 2013 and June 30, 2012. The Company recognized approximately $2.1 million in license fee revenue in connection with the amortization of up-front payments from Genzyme during each of the six months ended June 30, 2013 and June 30, 2012.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation in the financial statements and accompanying notes to the financial statements.
|
(3) MAYO LICENSE AGREEMENT
Overview
On June 11, 2009, the Company entered into a license agreement (the “License Agreement”) with MAYO Foundation for Medical Education and Research (“MAYO”). Under the License Agreement, MAYO granted the Company an exclusive, worldwide license within the field (the “Field”) of stool or blood based cancer diagnostics and screening (excluding a specified proteomic target) with regard to certain MAYO patents, and a non-exclusive worldwide license within the Field with regard to certain MAYO know-how. The licensed patents cover advances in sample processing, analytical testing and data analysis associated with non-invasive, stool-based DNA screening for colorectal cancer. Under the License Agreement, the Company assumes the obligation and expense of prosecuting and maintaining the licensed patents and is obligated to make commercially reasonable efforts to bring products covered by the license to market. Pursuant to the License Agreement, the Company granted MAYO two common stock purchase warrants with an exercise price of $1.90 per share covering 1,000,000 and 250,000 shares of common stock, respectively. The Company is also required to make payments to MAYO for up-front fees, fees once certain milestones are reached by the Company, and other payments as outlined in the License Agreement. In addition to the license to intellectual property owned by MAYO, the Company receives product development and research and development efforts from MAYO personnel. The Company determined that the payments made for intellectual property should not be capitalized as the future economic benefit derived from the transactions is uncertain. The Company is also obligated to make royalty payments to MAYO on potential future net sales of any products developed from the licensed technology.
Warrants
The warrants granted to MAYO were valued based on a Black-Scholes pricing model at the date of the grant. The warrants were granted with an exercise price of $1.90 per share of common stock. The grant to purchase 1,000,000 shares was immediately exercisable and the grant to purchase 250,000 shares vests and becomes exercisable over a four year period.
In March of 2010, MAYO partially exercised its warrant covering 1,000,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 200,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 86,596 shares leaving it with a net amount of 113,404 shares.
In September of 2010, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 300,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 97,853 shares leaving it with a net amount of 202,147 shares.
In June of 2011, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 250,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its rights with respect to 60,246 shares leaving it with a net amount of 189,754 shares.
In September of 2011, MAYO partially exercised this warrant by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 250,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 56,641 shares leaving it with a net amount of 193,359 shares. Following this exercise, the warrant covering 1,000,000 shares was fully exercised.
In January of 2013, MAYO partially exercised its warrant covering 250,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 14,008 shares leaving it with a net amount of 70,992 shares.
In June of 2013, MAYO partially exercised its warrant covering a remaining 165,000 shares by utilizing the cashless exercise provision contained in the warrant. As a result of this exercise for a gross amount of 85,000 shares, in lieu of paying a cash exercise price, MAYO forfeited its right with respect to 12,765 shares leaving it with a net amount of 72,235 shares. The warrant now covers a total of 80,000 shares.
Royalty Payments
The Company will make royalty payments to MAYO based on a percentage of net sales of products developed from the licensed technology starting in the third year of the agreement. Minimum royalty payments were $10,000 in 2012 and will be $25,000 per year through 2029, the year the last patent expires.
Other Payments
Other payments under the MAYO agreement include an upfront payment of $80,000, a milestone payment of $250,000 on the commencement of patient enrollment in FDA trials for the Company’s Cologuard pre-cancer and cancer screening test, and a $500,000 payment upon FDA approval of the Company’s Cologuard test. The upfront payment of $80,000 was made in the third quarter of 2009 and expensed to research and development in the second quarter of 2009. The Company began enrollment in its FDA trial in June of 2011 and the milestone payment of $250,000 was made in June of 2011 and expensed to research and development in the second quarter of 2011. It is uncertain as to when the FDA will approve the Company’s pre-cancer and cancer screening test. Therefore, the $500,000 milestone payment has not been recorded as a liability. The Company evaluates the status of the FDA trial at each reporting date to determine if a liability should be recorded for the milestone payment.
In addition, the Company is making payments to MAYO for research and development efforts. During the three and six months ended June 30, 2013, the Company made payments of $0.3 million and $0.5 million, respectively. At June 30, 2013 the Company recorded an estimated liability in the amount of $0.5 million for research and development efforts. During the three and six months ended June 30, 2012, the Company made payments of $0.2 million. At June 30, 2012 the Company recorded an estimated liability in the amount of $0.2 million for research and development efforts.
May 2012 Amendment
In May 2012 the Company expanded the relationship with MAYO through an amendment to the License Agreement. As part of the amendment, MAYO expanded the Company’s license to include all gastrointestinal cancers and diseases, and new cancer screening applications of stool- and blood-based testing. As consideration for the expanded license, the Company granted MAYO 97,466 shares of restricted stock, one quarter of which vested immediately, with the remainder to vest in three equal annual installments. The Company recognized $1.0 million in licensing expense during the twelve months ended December 31, 2012 in connection with the restricted stock grant due to the uncertainty in the license providing a future benefit.
As part of the amendment, the Company will also be responsible for making additional restricted stock grants to MAYO as certain milestones are met with respect to commercial launch of the Company’s second and third licensed products. Additionally, the Company will make milestone payments once certain sales levels are reached on the second and third licensed products. It is uncertain as to when these milestones will be met; therefore, the milestone payments have not been recorded as a liability. The Company evaluates the status of the milestone payments at each reporting date to determine if a liability should be recorded for the milestone payment.
|
(4) STOCK-BASED COMPENSATION
Stock-Based Compensation Plans
The Company maintains the 2010 Omnibus Long-Term Incentive Plan, the 2010 Employee Stock Purchase Plan, the 2000 Stock Option and Incentive Plan and the 2000 Employee Stock Purchase Plan (collectively, the “Stock Plans”).
Stock-Based Compensation Expense
The Company recorded $2.8 million and $3.8 million in stock-based compensation expense during the three and six months ended June 30, 2013 in connection with the amortization of restricted stock and restricted stock unit awards, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees, non-employee consultants and non-employee directors. The Company recorded $1.5 million and $2.5 million in stock-based compensation expense during the three and six months ended June 30, 2012 in connection with the amortization of restricted stock and restricted stock unit awards, stock purchase rights granted under the Company’s employee stock purchase plan and stock options granted to employees and non-employee directors.
In connection with the June 7, 2013 resignation of Laura Stoltenberg, the Company’s former Chief Commercial Officer, the Company modified the vesting of 100,000 shares of Ms. Stoltenberg’s previously unvested restricted stock units of which 41,250 of the restricted stock units vested upon the execution of the separation agreement, 10,000 will vest in March 2014, and the remaining 48,750 will vest in twenty-four equal monthly installments beginning in April 2014, subject to Ms. Stoltenberg’s continuing compliance with the terms of the separation agreement. Ms. Stoltenberg forfeited all other unvested restricted stock units and stock option awards. It was determined that the continuing compliance and service to be provided to the Company under the separation agreement was not substantive and, as a result, the Company recorded the full value of the modified restricted stock units as additional stock-based compensation expense in the second quarter of 2013.
Determining Fair Value
Valuation and Recognition - The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model based on the assumptions in the table below. The estimated fair value of employee stock options is recognized to expense using the straight-line method over the vesting period.
Expected Term - The Company uses the simplified calculation of expected life, described in the SEC’s Staff Accounting Bulletins 107 and 110, as the Company does not currently have sufficient historical exercise data on which to base an estimate of expected life. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.
Expected Volatility - Expected volatility is based on the Company’s historical stock volatility data over the expected term of the awards.
Risk-Free Interest Rate - The Company bases the risk-free interest rate used in the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury zero-coupon issues with an equivalent expected term.
Forfeitures - The Company records stock-based compensation expense only for those awards that are expected to vest. A forfeiture rate is estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. The Company’s forfeiture rate used in the six months ended June 30, 2013 was 2.76%. The Company’s forfeiture rate used in the six months ended June 30, 2012 was 1.38%.
The fair value of each restricted stock and restricted stock unit award is determined on the date of grant using the closing stock price on that day.
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
June 30, |
|
June 30, |
| ||||||||
|
|
2013 |
|
2012 |
|
2013 |
|
2012 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Option Plan Shares |
|
|
|
|
|
|
|
|
| ||||
Risk-free interest rates |
|
0.94% |
|
0.82% |
|
0.94% - 1.15% |
|
0.82% - 0.84% |
| ||||
Expected term (in years) |
|
6 |
|
6 |
|
6 |
|
6 |
| ||||
Expected volatility |
|
82.9% |
|
87.1% |
|
82.9% - 84.0% |
|
87.1% - 91.6% |
| ||||
Dividend yield |
|
0% |
|
0% |
|
0% |
|
0% |
| ||||
Weighted average fair value per share of options granted during the period |
|
$ |
6.55 |
|
$ |
7.38 |
|
$ |
7.66 |
|
$ |
6.86 |
|
|
|
|
|
|
|
|
|
|
| ||||
ESPP Shares |
|
|
|
|
|
|
|
|
| ||||
Risk-free interest rates |
|
0.11% - 0.20% |
|
0.19% - 0.27% |
|
0.11% - 0.20% |
|
0.19% - 0.27% |
| ||||
Expected term (in years) |
|
0.5-2 |
|
0.5 - 2 |
|
0.5-2 |
|
0.5 - 2 |
| ||||
Expected volatility |
|
39.1% - 45.6% |
|
39.6% - 54.9% |
|
39.1% - 45.6% |
|
39.6% - 54.9% |
| ||||
Dividend yield |
|
0% |
|
0% |
|
0% |
|
0% |
| ||||
Weighted average fair value per share of stock purchase rights granted during the period |
|
$ |
2.80 |
|
$ |
3.47 |
|
$ |
2.80 |
|
$ |
3.47 |
|
Stock Option and Restricted Stock Activity
A summary of stock option activity under the Stock Plans during the six months ended June 30, 2013 is as follows:
|
|
|
|
|
|
Weighted |
|
|
| ||
|
|
|
|
Weighted |
|
Average |
|
|
| ||
|
|
|
|
Average |
|
Remaining |
|
Aggregate |
| ||
|
|
|
|
Exercise |
|
Contractual |
|
Intrinsic |
| ||
Options |
|
Shares |
|
Price |
|
Term (Years) |
|
Value (1) |
| ||
(Aggregate intrinsic value in thousands) |
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
Outstanding, January 1, 2013 |
|
6,181,996 |
|
$ |
2.62 |
|
6.6 |
|
$ |
49,439 |
|
Granted |
|
240,570 |
|
$ |
10.72 |
|
|
|
|
| |
Exercised |
|
(98,869 |
) |
$ |
4.99 |
|
|
|
|
| |
Forfeited |
|
(74,250 |
) |
$ |
8.67 |
|
|
|
|
| |
Outstanding, June 30, 2013 |
|
6,249,447 |
|
$ |
2.83 |
|
6.2 |
|
$ |
69,266 |
|
|
|
|
|
|
|
|
|
|
| ||
Exercisable, June 30, 2013 |
|
5,205,858 |
|
$ |
1.84 |
|
5.8 |
|
$ |
62,849 |
|
|
|
|
|
|
|
|
|
|
| ||
Vested and expected to vest June 30, 2013 |
|
6,220,586 |
|
$ |
2.84 |
|
6.2 |
|
$ |
69,089 |
|
(1)The aggregate intrinsic value of options outstanding, exercisable and vested and expected to vest is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for options that had exercise prices that were lower than the $13.91 market price of the Company’s common stock at June 30, 2013. The total intrinsic value of options exercised during the six months ended June 30, 2013 was $0.5 million. The total intrinsic value of options exercised during the six months ended June 30, 2012 was $3.4 million.
As of June 30, 2013, there was $11.0 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under all Stock Plans. Total unrecognized compensation cost will be adjusted for future changes in forfeitures. The Company expects to recognize that cost over a weighted average period of 2.85 years.
A summary of restricted stock activity under the Stock Plans during the six months ended June 30, 2013 is as follows:
|
|
|
|
Weighted |
| |
|
|
Restricted |
|
Average Grant |
| |
|
|
Shares |
|
Date Fair Value |
| |
Outstanding, January 1, 2013 |
|
813,955 |
|
$ |
8.51 |
|
Granted |
|
581,124 |
|
$ |
10.77 |
|
Released |
|
(166,843 |
) |
$ |
8.63 |
|
Forfeited |
|
(352,836 |
) |
$ |
9.45 |
|
Outstanding, June 30, 2013 |
|
875,400 |
|
$ |
9.61 |
|
During the first quarter of 2012, the Company granted a total of 262,500 restricted stock units to certain executives that would have vested based upon the satisfaction of certain service and performance conditions. These performance conditions were not met and the awards were forfeited during the first quarter of 2013. The expense recorded through December 31, 2012 for these awards totaling $0.6 million was reversed during the first quarter of 2013 due to the forfeiture.
During the first quarter of 2013, the Company granted a total of 180,750 restricted stock units to certain executives that will vest based upon the satisfaction of certain service and performance conditions. The Company performed an evaluation of internal and external factors, and determined the number of shares that are most likely to vest based on the probability of which performance conditions will be met. The expense for the fair value of the awards that are expected to vest is being recognized ratably over the vesting period.
Warrants to purchase 75,000 shares of common stock were issued in connection with a consulting agreement in 2009. The warrants contain a performance condition and vest if the Company successfully receives FDA approval for its Cologuard test. The Company is uncertain if the performance conditions will be attained, and therefore no expense has been recorded on this warrant as of June 30, 2013. The exercise price of the warrant is $0.01.
|
(5) FAIR VALUE MEASUREMENTS
The FASB has issued authoritative guidance which requires that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy. The fair value hierarchy establishes and prioritizes the inputs used to measure fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs. Observable inputs are inputs that reflect the assumptions that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.
The three levels of the fair value hierarchy established are as follows:
Level 1 |
|
Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. |
|
|
|
Level 2 |
|
Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. |
|
|
|
Level 3 |
|
Unobservable inputs that reflect the Company’s assumptions about the assumptions that market participants would use in pricing the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available. |
Fixed-income securities and mutual funds are valued using a third party pricing agency. The valuation is based on observable inputs including pricing for similar assets and other observable market factors. There has been no material change from period to period. The estimated fair value of our long-term debt based on a market approach was approximately $1.0 million as of June 30, 2013 and December 31, 2012 and represent Level 2 measurements. When determining the estimated fair value of our long-term debt, we used market-based risk measurements, such as credit risk.
The following table presents the Company’s fair value measurements as of June 30, 2013 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Amounts in the table are in thousands.
|
|
|
|
Fair Value Measurement at June 30, 2013 Using: |
| ||||||||
|
|
|
|
Quoted Prices in Active |
|
Significant Other |
|
Significant Unobservable |
| ||||
|
|
Fair Value at |
|
Markets for Identical Assets |
|
Observable Inputs |
|
Inputs |
| ||||
Description |
|
June 30, 2013 |
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Cash and cash equivalents |
|
|
|
|
|
|
|
|
| ||||
Cash and money market |
|
$ |
12,567 |
|
$ |
12,567 |
|
$ |
— |
|
$ |
— |
|
Certificates of deposit |
|
8,951 |
|
— |
|
8,951 |
|
— |
| ||||
Available-for-Sale |
|
|
|
|
|
|
|
|
| ||||
Marketable securities |
|
|
|
|
|
|
|
|
| ||||
U.S. government agency securities |
|
49,196 |
|
— |
|
49,196 |
|
— |
| ||||
Corporate bonds |
|
73,736 |
|
— |
|
73,736 |
|
— |
| ||||
Certificates of deposit |
|
8,284 |
|
— |
|
8,284 |
|
— |
| ||||
Commercial paper |
|
4,995 |
|
— |
|
4,995 |
|
— |
| ||||
Total |
|
$ |
157,729 |
|
$ |
12,567 |
|
$ |
145,162 |
|
$ |
— |
|
The following table presents the Company’s fair value measurements as of December 31, 2012 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Amounts in the table are in thousands.
|
|
|
|
Fair Value Measurement at December 31, 2012 Using: |
| ||||||||
|
|
|
|
Quoted Prices in Active |
|
Significant Other |
|
Significant Unobservable |
| ||||
|
|
Fair Value at |
|
Markets for Identical Assets |
|
Observable Inputs |
|
Inputs |
| ||||
Description |
|
December 31, 2012 |
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Cash and cash equivalents |
|
|
|
|
|
|
|
|
| ||||
Cash and money market |
|
$ |
13,095 |
|
$ |
13,095 |
|
$ |
— |
|
$ |
— |
|
Corporate bonds |
|
250 |
|
— |
|
250 |
|
— |
| ||||
Available-for-Sale |
|
|
|
|
|
|
|
|
| ||||
Marketable securities |
|
|
|
|
|
|
|
|
| ||||
U.S. government agency securities |
|
44,308 |
|
— |
|
44,308 |
|
— |
| ||||
Certificates of deposit |
|
5,939 |
|
— |
|
5,939 |
|
— |
| ||||
Corporate bonds |
|
43,330 |
|
— |
|
43,330 |
|
— |
| ||||
Commercial paper |
|
1,199 |
|
— |
|
1,199 |
|
— |
| ||||
Total |
|
$ |
108,121 |
|
$ |
13,095 |
|
$ |
95,026 |
|
$ |
— |
|
As of June 30, 2013 and December 31, 2012 there were available-for-sale securities in a continuous unrealized loss position for less than twelve months where the total unrealized losses were $58,184 and $4,800 respectively. At June 30, 2013 and December 31, 2012 there were no available-for-sale securities in a continuous loss position for greater than twelve months.
The following summarizes contractual underlying maturities of the Company’s available-for-sale investments in debt securities at June 30, 2013 (in thousands):
|
|
Cost |
|
Fair Value |
| ||
Due in one year or less |
|
$ |
71,915 |
|
$ |
71,940 |
|
Due after one year through two years |
|
64,279 |
|
64,271 |
| ||
|
|
$ |
136,194 |
|
$ |
136,211 |
|
|
(6) EQUITY
On June 21, 2013, the Company completed an underwritten public offering of 6,325,000 shares of common stock at a price of $12.35 per share to the public. The Company received approximately $73.3 million of net proceeds from the offering, after deducting $4.8 million for the underwriting discount and other stock issuance costs paid by the Company.
|
(7) OPERATING LEASE
During the second quarter of 2013, the Company entered into a five year lease for a 29,000 square foot facility in Madison, Wisconsin to house our commercial lab operations. This lease contains periodic rent escalation adjustments and includes provisions for tenant improvements. The Company has two, five year options to extend the term of the lease.
Future minimum payments under the operating lease are as follows as of June 30, 2013. Amounts included in the table are in thousands.
Year Ending December 31, |
|
|
| |
2013 |
|
$ |
112 |
|
2014 |
|
676 |
| |
2015 |
|
680 |
| |
2016 |
|
684 |
| |
2017 |
|
689 |
| |
2018 |
|
578 |
| |
Total lease obligations |
|
$ |
3,419 |
|
|
(8) RELATED PARTY TRANSACTIONS
During the three months ended September 30, 2012, the Company entered into a one year consulting agreement with a non-employee director under which the director provides advisory services in support of the Company’s commercialization activities. In accordance with the agreement, the Company granted a restricted stock award for 4,873 shares of common stock that vests over one year, and will make cash payments totaling $60,000 over the one year term of the agreement.
|
(9) INCOME TAXES
The Company is subject to taxation in the U.S. and various state jurisdictions. All of the Company’s tax years are subject to examination by the U.S. and state tax authorities due to the carryforward of unutilized net operating losses.
Under financial accounting standards, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities using the enacted tax rates. Deferred income tax expense or benefit represents the change in the deferred tax assets or liabilities from period to period.
A valuation allowance to reduce the deferred tax assets is reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has incurred significant losses since its inception and due to the uncertainty of the amount and timing of future taxable income, management has determined that a full valuation allowance at June 30, 2013 is necessary to reduce the tax assets to the amount that is more likely than not to be realized. Due to the existence of the valuation allowance, future changes in our unrecognized tax benefits will not impact the Company’s effective tax rate.
The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. At June 30, 2013 the Company had no unrecognized tax benefits, nor are there any tax positions where it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the 12 months following June 30, 2013.
|
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers cash on hand, demand deposits in bank, money market funds, and all highly liquid investments with an original maturity of 90 days or less to be cash and cash equivalents. The Company had no restricted cash at June 30, 2013 and December 31, 2012.
Marketable Securities
Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such designation as of each balance sheet date. Debt securities carried at amortized cost are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Marketable equity securities and debt securities not classified as held-to-maturity are classified as available-for-sale. Available-for-sale securities are carried at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity computed under the straight-line method, which approximates the effective interest method. Such amortization is included in investment income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in investment income. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in investment income.
At June 30, 2013 and December 31, 2012, the Company’s investments were comprised of fixed income investments and all were deemed available-for-sale. The objectives of the Company’s investment strategy are to provide liquidity and safety of principal while striving to achieve the highest rate of return consistent with these two objectives. The Company’s investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. Investments in which the Company has the ability and intent, if necessary, to liquidate in order to support its current operations (including those with a contractual term greater than one year from the date of purchase) are classified as current. All of the Company’s investments are considered current. There were no realized losses for the six months ended June 30, 2013 and June 30, 2012. Realized gains were $2,760 and $2,528 for the six months ended June 30, 2013 and 2012, respectively. Unrealized gains or losses on investments are recorded in other comprehensive loss.
Available-for-sale securities at June 30, 2013 consist of the following:
|
|
June 30, 2013 |
| ||||||||||
(In thousands) |
|
Amortized |
|
Gains in |
|
Losses in |
|
Estimated |
| ||||
U.S. government agency securities |
|
$ |
49,156 |
|
$ |
40 |
|
$ |
— |
|
$ |
49,196 |
|
Corporate bonds |
|
73,771 |
|
— |
|
(35 |
) |
73,736 |
| ||||
Certificates of deposit |
|
8,272 |
|
12 |
|
— |
|
8,284 |
| ||||
Commercial paper |
|
4,995 |
|
— |
|
— |
|
4,995 |
| ||||
Total available-for-sale securities |
|
$ |
136,194 |
|
$ |
52 |
|
$ |
(35 |
) |
$ |
136,211 |
|
Available-for-sale securities at December 31, 2012 consist of the following:
|
|
December 31, 2012 |
| ||||||||||
(In thousands) |
|
Amortized |
|
Gains in |
|
Losses in |
|
Estimated |
| ||||
U.S. government agency securities |
|
$ |
44,270 |
|
$ |
38 |
|
$ |
— |
|
$ |
44,308 |
|
Corporate bonds |
|
43,303 |
|
27 |
|
— |
|
43,330 |
| ||||
Certificates of deposit |
|
5,926 |
|
13 |
|
— |
|
5,939 |
| ||||
Commercial paper |
|
1,199 |
|
— |
|
— |
|
1,199 |
| ||||
Total available-for-sale securities |
|
$ |
94,698 |
|
$ |
78 |
|
$ |
— |
|
$ |
94,776 |
|
Net Loss Per Share
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect due to net losses for each period:
|
|
June 30, |
| ||
(In thousands) |
|
2013 |
|
2012 |
|
Shares issuable upon exercise of stock options |
|
6,249 |
|
6,320 |
|
Shares issuable upon exercise of outstanding warrants (1) |
|
155 |
|
325 |
|
Shares issuable upon the release of restricted stock awards |
|
875 |
|
884 |
|
Shares issuable upon the vesting of restricted stock awards related to a licensing agreement |
|
49 |
|
73 |
|
|
|
7,328 |
|
7,602 |
|
(1) At June 30, 2013, represents warrants to purchase 80,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement. At June 30, 2012, represents warrants to purchase 250,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.
Revenue Recognition
License fees. License fees for the licensing of product rights are recorded as deferred revenue upon receipt of cash and recognized as revenue on a straight-line basis over the license period. As more fully described in the 2012 Form 10-K, in connection with our January 2009 strategic transaction with Genzyme Corporation, Genzyme agreed to pay us a total of $18.5 million, of which $16.65 million was paid on January 27, 2009 and $1.85 million was subject to a holdback by Genzyme to satisfy certain potential indemnification obligations in exchange for the assignment and licensing of certain intellectual property to Genzyme. The Company’s on-going performance obligations to Genzyme under the Collaboration, License and Purchase Agreement (the “CLP Agreement”), as described below, including its obligation to deliver through licenses certain intellectual property improvements to Genzyme, if improvements are made during the initial five-year collaboration period, were deemed to be undelivered elements of the CLP Agreement on the date of closing. Accordingly, the Company deferred the initial $16.65 million in cash received at closing and is amortizing that up-front payment on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014. The Company received the first holdback amount of $962,000, which included accrued interest due, from Genzyme during the first quarter of 2010. The Company received the second holdback amount of $934,250, which included accrued interest due, from Genzyme during the third quarter of 2010. The amounts were deferred and are being amortized on a straight-line basis into revenue over the remaining term of the collaboration at the time of receipt.
In addition, Genzyme purchased 3,000,000 shares of common stock on January 27, 2009 for $2.00 per share, representing a premium of $0.51 per share above the closing price of the Company’s common stock on that date of $1.49 per share. The aggregate premium paid by Genzyme over the closing price of the Company’s common stock on the date of the transaction of $1.53 million is deemed to be a part of the total consideration for the CLP Agreement. Accordingly, the Company deferred the aggregate $1.53 million premium and is amortizing that amount on a straight-line basis into revenue over the initial five-year collaboration period ending in January 2014.
The Company recognized approximately $1.0 million in license fee revenue in connection with the amortization of the up-front payments from Genzyme, during each of the three months ended June 30, 2013 and June 30, 2012. The Company recognized approximately $2.1 million in license fee revenue in connection with the amortization of up-front payments from Genzyme during each of the six months ended June 30, 2013 and June 30, 2012.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation in the financial statements and accompanying notes to the financial statements.
|
|
|
June 30, 2013 |
| ||||||||||
(In thousands) |
|
Amortized |
|
Gains in |
|
Losses in |
|
Estimated |
| ||||
U.S. government agency securities |
|
$ |
49,156 |
|
$ |
40 |
|
$ |
— |
|
$ |
49,196 |
|
Corporate bonds |
|
73,771 |
|
— |
|
(35 |
) |
73,736 |
| ||||
Certificates of deposit |
|
8,272 |
|
12 |
|
— |
|
8,284 |
| ||||
Commercial paper |
|
4,995 |
|
— |
|
— |
|
4,995 |
| ||||
Total available-for-sale securities |
|
$ |
136,194 |
|
$ |
52 |
|
$ |
(35 |
) |
$ |
136,211 |
|
|
|
December 31, 2012 |
| ||||||||||
(In thousands) |
|
Amortized |
|
Gains in |
|
Losses in |
|
Estimated |
| ||||
U.S. government agency securities |
|
$ |
44,270 |
|
$ |
38 |
|
$ |
— |
|
$ |
44,308 |
|
Corporate bonds |
|
43,303 |
|
27 |
|
— |
|
43,330 |
| ||||
Certificates of deposit |
|
5,926 |
|
13 |
|
— |
|
5,939 |
| ||||
Commercial paper |
|
1,199 |
|
— |
|
— |
|
1,199 |
| ||||
Total available-for-sale securities |
|
$ |
94,698 |
|
$ |
78 |
|
$ |
— |
|
$ |
94,776 |
|
|
|
June 30, |
| ||
(In thousands) |
|
2013 |
|
2012 |
|
Shares issuable upon exercise of stock options |
|
6,249 |
|
6,320 |
|
Shares issuable upon exercise of outstanding warrants (1) |
|
155 |
|
325 |
|
Shares issuable upon the release of restricted stock awards |
|
875 |
|
884 |
|
Shares issuable upon the vesting of restricted stock awards related to a licensing agreement |
|
49 |
|
73 |
|
|
|
7,328 |
|
7,602 |
|
(1) At June 30, 2013, represents warrants to purchase 80,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement. At June 30, 2012, represents warrants to purchase 250,000 shares of common stock issued under a license agreement and warrants to purchase 75,000 shares of common stock issued under a consulting agreement.
|
|
|
Three Months Ended |
|
Six Months Ended |
| ||||||||
|
|
June 30, |
|
June 30, |
| ||||||||
|
|
2013 |
|
2012 |
|
2013 |
|
2012 |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Option Plan Shares |
|
|
|
|
|
|
|
|
| ||||
Risk-free interest rates |
|
0.94% |
|
0.82% |
|
0.94% - 1.15% |
|
0.82% - 0.84% |
| ||||
Expected term (in years) |
|
6 |
|
6 |
|
6 |
|
6 |
| ||||
Expected volatility |
|
82.9% |
|
87.1% |
|
82.9% - 84.0% |
|
87.1% - 91.6% |
| ||||
Dividend yield |
|
0% |
|
0% |
|
0% |
|
0% |
| ||||
Weighted average fair value per share of options granted during the period |
|
$ |
6.55 |
|
$ |
7.38 |
|
$ |
7.66 |
|
$ |
6.86 |
|
|
|
|
|
|
|
|
|
|
| ||||
ESPP Shares |
|
|
|
|
|
|
|
|
| ||||
Risk-free interest rates |
|
0.11% - 0.20% |
|
0.19% - 0.27% |
|
0.11% - 0.20% |
|
0.19% - 0.27% |
| ||||
Expected term (in years) |
|
0.5-2 |
|
0.5 - 2 |
|
0.5-2 |
|
0.5 - 2 |
| ||||
Expected volatility |
|
39.1% - 45.6% |
|
39.6% - 54.9% |
|
39.1% - 45.6% |
|
39.6% - 54.9% |
| ||||
Dividend yield |
|
0% |
|
0% |
|
0% |
|
0% |
| ||||
Weighted average fair value per share of stock purchase rights granted during the period |
|
$ |
2.80 |
|
$ |
3.47 |
|
$ |
2.80 |
|
$ |
3.47 |
|
|
|
|
|
|
|
Weighted |
|
|
| ||
|
|
|
|
Weighted |
|
Average |
|
|
| ||
|
|
|
|
Average |
|
Remaining |
|
Aggregate |
| ||
|
|
|
|
Exercise |
|
Contractual |
|
Intrinsic |
| ||
Options |
|
Shares |
|
Price |
|
Term (Years) |
|
Value (1) |
| ||
(Aggregate intrinsic value in thousands) |
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
| ||
Outstanding, January 1, 2013 |
|
6,181,996 |
|
$ |
2.62 |
|
6.6 |
|
$ |
49,439 |
|
Granted |
|
240,570 |
|
$ |
10.72 |
|
|
|
|
| |
Exercised |
|
(98,869 |
) |
$ |
4.99 |
|
|
|
|
| |
Forfeited |
|
(74,250 |
) |
$ |
8.67 |
|
|
|
|
| |
Outstanding, June 30, 2013 |
|
6,249,447 |
|
$ |
2.83 |
|
6.2 |
|
$ |
69,266 |
|
|
|
|
|
|
|
|
|
|
| ||
Exercisable, June 30, 2013 |
|
5,205,858 |
|
$ |
1.84 |
|
5.8 |
|
$ |
62,849 |
|
|
|
|
|
|
|
|
|
|
| ||
Vested and expected to vest June 30, 2013 |
|
6,220,586 |
|
$ |
2.84 |
|
6.2 |
|
$ |
69,089 |
|
(1)The aggregate intrinsic value of options outstanding, exercisable and vested and expected to vest is calculated as the difference between the exercise price of the underlying options and the market price of the Company’s common stock for options that had exercise prices that were lower than the $13.91 market price of the Company’s common stock at June 30, 2013. The total intrinsic value of options exercised during the six months ended June 30, 2013 was $0.5 million. The total intrinsic value of options exercised during the six months ended June 30, 2012 was $3.4 million.
|
|
|
|
Weighted |
| |
|
|
Restricted |
|
Average Grant |
| |
|
|
Shares |
|
Date Fair Value |
| |
Outstanding, January 1, 2013 |
|
813,955 |
|
$ |
8.51 |
|
Granted |
|
581,124 |
|
$ |
10.77 |
|
Released |
|
(166,843 |
) |
$ |
8.63 |
|
Forfeited |
|
(352,836 |
) |
$ |
9.45 |
|
Outstanding, June 30, 2013 |
|
875,400 |
|
$ |
9.61 |
|
|
The following table presents the Company’s fair value measurements as of June 30, 2013 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Amounts in the table are in thousands.
|
|
|
|
Fair Value Measurement at June 30, 2013 Using: |
| ||||||||
|
|
|
|
Quoted Prices in Active |
|
Significant Other |
|
Significant Unobservable |
| ||||
|
|
Fair Value at |
|
Markets for Identical Assets |
|
Observable Inputs |
|
Inputs |
| ||||
Description |
|
June 30, 2013 |
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Cash and cash equivalents |
|
|
|
|
|
|
|
|
| ||||
Cash and money market |
|
$ |
12,567 |
|
$ |
12,567 |
|
$ |
— |
|
$ |
— |
|
Certificates of deposit |
|
8,951 |
|
— |
|
8,951 |
|
— |
| ||||
Available-for-Sale |
|
|
|
|
|
|
|
|
| ||||
Marketable securities |
|
|
|
|
|
|
|
|
| ||||
U.S. government agency securities |
|
49,196 |
|
— |
|
49,196 |
|
— |
| ||||
Corporate bonds |
|
73,736 |
|
— |
|
73,736 |
|
— |
| ||||
Certificates of deposit |
|
8,284 |
|
— |
|
8,284 |
|
— |
| ||||
Commercial paper |
|
4,995 |
|
— |
|
4,995 |
|
— |
| ||||
Total |
|
$ |
157,729 |
|
$ |
12,567 |
|
$ |
145,162 |
|
$ |
— |
|
The following table presents the Company’s fair value measurements as of December 31, 2012 along with the level within the fair value hierarchy in which the fair value measurements in their entirety fall. Amounts in the table are in thousands.
|
|
|
|
Fair Value Measurement at December 31, 2012 Using: |
| ||||||||
|
|
|
|
Quoted Prices in Active |
|
Significant Other |
|
Significant Unobservable |
| ||||
|
|
Fair Value at |
|
Markets for Identical Assets |
|
Observable Inputs |
|
Inputs |
| ||||
Description |
|
December 31, 2012 |
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
| ||||
|
|
|
|
|
|
|
|
|
| ||||
Cash and cash equivalents |
|
|
|
|
|
|
|
|
| ||||
Cash and money market |
|
$ |
13,095 |
|
$ |
13,095 |
|
$ |
— |
|
$ |
— |
|
Corporate bonds |
|
250 |
|
— |
|
250 |
|
— |
| ||||
Available-for-Sale |
|
|
|
|
|
|
|
|
| ||||
Marketable securities |
|
|
|
|
|
|
|
|
| ||||
U.S. government agency securities |
|
44,308 |
|
— |
|
44,308 |
|
— |
| ||||
Certificates of deposit |
|
5,939 |
|
— |
|
5,939 |
|
— |
| ||||
Corporate bonds |
|
43,330 |
|
— |
|
43,330 |
|
— |
| ||||
Commercial paper |
|
1,199 |
|
— |
|
1,199 |
|
— |
| ||||
Total |
|
$ |
108,121 |
|
$ |
13,095 |
|
$ |
95,026 |
|
$ |
— |
|
The following summarizes contractual underlying maturities of the Company’s available-for-sale investments in debt securities at June 30, 2013 (in thousands):
|
|
Cost |
|
Fair Value |
| ||
Due in one year or less |
|
$ |
71,915 |
|
$ |
71,940 |
|
Due after one year through two years |
|
64,279 |
|
64,271 |
| ||
|
|
$ |
136,194 |
|
$ |
136,211 |
|
|
Future minimum payments under the operating lease are as follows as of June 30, 2013. Amounts included in the table are in thousands.
Year Ending December 31, |
|
|
| |
2013 |
|
$ |
112 |
|
2014 |
|
676 |
| |
2015 |
|
680 |
| |
2016 |
|
684 |
| |
2017 |
|
689 |
| |
2018 |
|
578 |
| |
Total lease obligations |
|
$ |
3,419 |
|
|
|
|
|
|
|
|
|
|
|
|
|